Since this issue has not been addressed in PCOS patients who are in fact one of the target groups for these products, this study was designed to compare the ART outcome between the two pure FSH preparations, Gonal-F (recombinant FSH) and Fostimon (urinary hp-FSH) available in Iran. This evidence concerns the gene BRD2 and polycystic ovary syndrome.